We carried out a 2‐step, retrospective analysis to: (i) assess the influence of transfusion dependence and Hb levels on overall survival (OS) and non‐leukemic death in an untreated cohort of patients with del(5q) MDS (observational study)6 and (ii) evaluate the efficacy and QoL benefits of lenalidomide in a subset of Italian patients with TI del(5q) MDS enrolled in the phase 2 RevMDS trial (interventional study) 4. Here, GSTM1 is linked to myelodysplastic syndrome.